Engineering Cell-Specific Protein Delivery Vehicles for Erythroid Lineage Cells

Area of Science:

• Biotechnology
• Cell Biology
• Drug Delivery

Background:

• Biologics like proteins offer therapeutic potential but face delivery challenges due to poor membrane permeance, limiting intracellular applications.
• Erythroid lineage cells present unique difficulties for cargo delivery owing to their distinct cytoskeleton and lack of endocytosis in mature forms.
• Previous attempts using miniature proteins for bioPROTAC delivery to erythroid cells showed promise but suffered from low efficiency and specificity.

Purpose of the Study:

• To comprehensively assess various delivery systems for cargo translocation into erythroid precursor cells.
• To investigate the impact of targeting cell-surface receptors on the efficiency and specificity of these delivery vehicles.
• To advance the understanding of protein delivery mechanisms into challenging cell types.

Main Methods:

• Evaluation of cell penetrating peptides (CPPs), CPP additives, bacterial toxins, and contractile injection systems for cargo delivery.
• Exploration of cell-surface receptor targeting strategies to enhance delivery to erythroid cells.
• Comparative analysis of delivery vehicle performance with and without receptor-specific targeting.

Main Results:

• Certain delivery vehicles demonstrated enhanced efficiency when targeted to specific cell surface receptors on erythroid precursor cells.
• Other delivery systems did not show significant improvement through receptor-targeting strategies.
• The study identified key factors influencing cargo delivery into difficult-to-transfect cell types.

Conclusions:

• The findings provide critical insights into optimizing protein and biologic delivery to challenging cell types, particularly erythroid precursors.
• Cell-surface receptor targeting can be a beneficial strategy for specific delivery vehicles, but its effectiveness varies.
• This research contributes to the development of more effective intracellular biologic therapies by addressing delivery barriers.